Wells Fargo
SKYE icon

Wells Fargo’s Skye Bioscience SKYE Stock Holding History

Wells Fargo’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– – – 7268
2026
Q1 		– Hold
0
– -$1 – 7500
2025
Q4 		– Hold
0
– – – 7085
2025
Q3 		– Sell
-47
Closed -$1.42K – 6958
2025
Q2 		$1.57K Sell
47
-1,390
-97% -$23K ﹤0.01% 6243
2025
Q1 		$18.3K Buy
1,437
+37
+3% +$808 ﹤0.01% 5738
2024
Q4 		$31.7K Buy
1,400
+461
+49% +$15.4K ﹤0.01% 5628
2024
Q3 		$29.4K Buy
939
+30
+3% +$1.35K ﹤0.01% 5531
2024
Q2 		$58.2K Buy
+909
New +$86.3K ﹤0.01% 5238

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wells Fargo's SKYE Position: Q2 2026 in Review

Wells Fargo held its Skye Bioscience (SKYE) position steady in Q2 2026 at 0 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #7268.

Wells Fargo first reported a position in SKYE in Q2 2024 and has held it in 5 quarters since. The position peaked at $58.2K in Q2 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Wells Fargo held 0 shares of Skye Bioscience worth $1 as of Q2 2026.
  • Wells Fargo left its Skye Bioscience share count unchanged in Q2 2026.
  • Skye Bioscience made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #7268 holding.
  • Wells Fargo first reported a position in Skye Bioscience in Q2 2024 and has held it in 5 quarters since.
  • Wells Fargo's Skye Bioscience position peaked at $58.2K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.